Nano-X Imaging Ltd. (NASDAQ:NNOX) Receives Average Rating of “Moderate Buy” from Brokerages

Nano-X Imaging Ltd. (NASDAQ:NNOX) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.00.

Several research analysts recently weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Nano-X Imaging in a research note on Monday, April 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nano-X Imaging in a research report on Friday, April 10th. Alliance Global Partners reissued a “neutral” rating and issued a $3.00 price target (down from $5.00) on shares of Nano-X Imaging in a report on Tuesday. Finally, Zacks Research upgraded shares of Nano-X Imaging from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd.

Nano-X Imaging Price Performance

Shares of NASDAQ:NNOX opened at $1.24 on Wednesday. The stock has a market cap of $86.29 million, a price-to-earnings ratio of -0.78 and a beta of 1.24. Nano-X Imaging has a 12 month low of $0.73 and a 12 month high of $5.69. The stock’s 50 day moving average price is $1.68 and its 200 day moving average price is $2.28.

Nano-X Imaging (NASDAQ:NNOX) last issued its quarterly earnings results on Thursday, June 25th. The company reported ($0.16) earnings per share (EPS) for the quarter. Nano-X Imaging had a negative net margin of 716.44% and a negative return on equity of 70.96%. The firm had revenue of $4.31 million for the quarter. On average, sell-side analysts expect that Nano-X Imaging will post -0.6 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Nano-X Imaging by 8.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,182 shares of the company’s stock worth $182,000 after acquiring an additional 2,724 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Nano-X Imaging by 20.5% during the second quarter. The Manufacturers Life Insurance Company now owns 22,433 shares of the company’s stock worth $116,000 after purchasing an additional 3,818 shares during the period. Russell Investments Group Ltd. raised its position in shares of Nano-X Imaging by 62.1% during the third quarter. Russell Investments Group Ltd. now owns 13,787 shares of the company’s stock worth $51,000 after purchasing an additional 5,283 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Nano-X Imaging by 64.6% during the third quarter. BNP Paribas Financial Markets now owns 19,743 shares of the company’s stock valued at $73,000 after purchasing an additional 7,749 shares during the last quarter. Finally, Mariner LLC boosted its position in shares of Nano-X Imaging by 70.5% in the 4th quarter. Mariner LLC now owns 20,825 shares of the company’s stock valued at $58,000 after purchasing an additional 8,614 shares during the period. Institutional investors own 21.49% of the company’s stock.

Trending Headlines about Nano-X Imaging

Here are the key news stories impacting Nano-X Imaging this week:

• Positive Sentiment: Nano-X said new clinical study data for its Nanox.AI cardiac solution will be presented at SCCT 2026, with Brigham and Women’s Hospital abstracts highlighting high agreement with expert assessment and potential use in preventive care. Article: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
• Neutral Sentiment: Alliance Global Partners reiterated a “Neutral” rating on Nano-X Imaging, but lowered its price target to $3 from $5, signaling reduced near-term confidence even though it still implies upside from current levels. Article: Nano-X Imaging’s (NNOX) “Neutral” Rating Reiterated at Alliance Global Partners
• Negative Sentiment: Multiple law firms announced or reiterated a federal securities class action against Nano-X Imaging, with claims tied to purchases made between March 31, 2025 and April 17, 2026. Article: Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers – NNOX
• Negative Sentiment: Several firms, including Rosen, Kirby McInerney, Glancy Prongay Wolke & Rotter, and Faruqi & Faruqi, are urging investors to act before the August 11, 2026 lead-plaintiff deadline, keeping legal risk in focus. Article: REMINDER: Nano-X Imaging Ltd. Investors With Significant Losses Must Act By August 11, 2026

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.